U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07331844) titled 'BTX-A and Mirror Therapy for Chronic Stroke Spasticity' on Feb. 25, 2025.
Brief Summary: Stroke is one of the leading causes of disability worldwide, particularly affecting the upper extremities and thus negatively impacting patients' activities of daily living and quality of life. Upper extremity spasticity, characterized by increased muscle tone and tendon reflexes, leads to functional limitations. While Botulinum Toxin Type A (BTX-A) is widely used to manage spasticity and can temporarily alleviate symptoms, it does not directly support neuroplasticity and often requires repeated injections.
Mirror therapy (MT) has emerged as a ...